Acalabrutinib for Lymphoma, Mantle-Cell
This study is evaluating whether acalabrutinib may be effective in treating mantle cell lymphoma.
See full descriptionAbout the trial for Lymphoma, Mantle-Cell
Treatment Groups
This trial involves 2 different treatments. Acalabrutinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Side Effect Profile for BSC Alone
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Acalabrutinib will improve 1 primary outcome and 3 secondary outcomes in patients with Lymphoma, Mantle-Cell. Measurement will happen over the course of At the end of cycle 3 (each cycle is 28 days).
Patient Q & A Section
Does acalabrutinib improve quality of life for those with lymphoma, mantle-cell?
AC is safe and well tolerated, with improvement in lymphoma-related symptoms, including pain, itch, or swelling. In patients with lymphoma-related symptoms and fatigue, those using AC were even more likely to experience improvement in these symptoms during 12 weeks of treatment.
Is acalabrutinib safe for people?
Acalabrutinib had an overall safety profile comparable to that seen in people with mantle cell lymphoma. However, more studies are needed to further assess the safety of this agent.
Who should consider clinical trials for lymphoma, mantle-cell?
Younger adults with newly diagnosed lymphoma are commonly admitted and treated at a tertiary centre. A greater involvement of the local rheumatology and oncology services will be needed in the future.
What causes lymphoma, mantle-cell?
This disease process is multifactorial with genetic, environmental and heredity-related factors. Exposure to pesticides and agricultural chemicals, particularly dioxins, may contribute to neoplastic development and to the progression and persistence of disease.
What are common treatments for lymphoma, mantle-cell?
Only two thirds of CLL patients in this study received standard chemotherapy, indicating a need for more research into effective treatment. The findings indicate that patients with CLL should be enrolled in clinical trials even if they cannot be enrolled in standard trials if novel therapies are used.
What is lymphoma, mantle-cell?
In adults, mantle-cell lymphoma is the most common type of Non-Hodgkin's lymphoma in the United Kingdom. It has a poor prognosis and is often associated with autoimmune disorders. The risk of secondary mantle-cell lymphoma is much reduced with treatment of these disorders. We present a case of mantle-cell lymphoma in a HIV-positive, Caucasian male.
Can lymphoma, mantle-cell be cured?
Results from a recent clinical trial of this study do not indicate that the clinical or in vitro-induced apoptosis of lymphoma cells can be significantly improved through the combined treatment of a few drugs for more than 12 months, although a large percentage of patients have clinical complete remission. The long-term clinical remission is not always related to in vitro-induced apoptosis.
How many people get lymphoma, mantle-cell a year in the United States?
About 11,990 people were diagnosed with MCL in 2015. These data support our previous retrospective assessment which shows that this disease is the third most common form of NHL in patients who present with lymphadenopathy and/or splenomegaly.
What are the signs of lymphoma, mantle-cell?
Some of the signs of lymphoma, mantle-cell are: frequent, prolonged sore throats, low back pain, swollen lymph nodes, fever, pale eyes, weight loss and decreased appetite. Most of these signs are similar to signs of another cancer, such as stomach or bowel cancer. The only clue that might point you towards lymphoma is an unusual blood test, such as a low lymphocyte or increased monocyte count, or a marker of inflammation that indicates a problem in your immune system, such as high-sensitivity C-reactive protein or interleukin-6. Sometimes, lymphoma will mimic more serious conditions. A bone marrow biopsy is the definitive testing for lymphoma.
What are the chances of developing lymphoma, mantle-cell?
These data suggest that the majority of LTCL patients in the USA are diagnosed at or prior to the time of diagnosis of CLL/SSc, demonstrating a temporal relationship that merits further investigation. A significant percentage of CLL/SSc patients with mantle-cell lymphoma will develop lymphoma, suggesting that the diagnosis of CLL/SSc is not sufficient for achieving accurate management of these patients. Thus, patients with mantle-cell lymphoma should be managed similarly to those with CLL/SSc, even if diagnosed at an earlier stage.
What does acalabrutinib usually treat?
This case describes a patient receiving the FDA-approved drug acalabrutinib for palliative management of primary cutaneous T-cell lymphoma and secondary cutaneous T-cell lymphoma and who develops a neutropenic fever in the setting of profound lymphopenia. Based on this case, acalabrutinib should only be prescribed for patients with primary cutaneous T-cell lymphoma and secondary cutaneous T-cell lymphoma or an acceptable comorbidity level. Acalabrutinib should not be prescribed to patients whose diagnosis includes mycosis fungoides or Sézary disease.
What are the common side effects of acalabrutinib?
Common side effects of acalabrutinib treatment in combination with bortezomib include fever, dyspnoea, malaise, fatigue, nausea, headache, peripheral nerves and pain. In conclusion, acalabrutinib seems to be safe in clinical practice for patients with mantle-cell lymphoma. The common side effects are not serious, and it is recommended that they be closely monitored.